Zydus get DCGI nod to market rabies drug
Update: 2019-09-04 00:26 IST
New Delhi: Zydus Cadila on Tuesday said it has received marketing authorisation for Twinrab, used for treating rabies, from the Drug Controller General of India .
"The novel biologic which will be marketed under the brand name, Twinrab, is indicated in combination with rabies vaccine for rabies post-exposure prophylaxis," Zydus Cadila said in a statement.
Rabies, a viral disease which gets transmitted through the bite of a rabid animal, affects the central nervous system.
Zydus said in 2008, it had entered into an agreement with the World Health Organisation (WHO) to explore opportunities in the development of a cocktail of monoclonal antibodies for the treatment of rabies.